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• The higher BUP-to-NBUP ratio (0.7—19.19) than adults (0.165—1.4) has been observed in newborn patients studied.  
It might be due to immature hepatic function in newborns and compliance to BUP sublingual administration.
• ID 6 showed the two highest BUP/NBUP ratio among 12 newborns examined. It might be due to large percentage of 
BUP dose not being administrated (medical record errors) and/or analytical measurement errors.
• Large individual variability has been observed in sublingual bioavailability . Higher values of bioavailability 
observed might be due to underestimated CLsub and/or overestimated CLiv. 
• Sublingual bioavailability was estimated from 13.5% to 56.6% in the 9 neonates treated exclusively with BUP during 
the first postnatal month. The bioavailability of these 9 neonates except ID 28 was increased gradually by 13% at 
least during this period. Linear increase trend is observed when plotting sublingual bioavailability versus PMA for 
each of the 9 neonates studied. 
• Sublingual bioavailability of ID 13, 22, and 27 showed less linear increase with PMA, compared with that of all other 
patients. It might be due to enzyme induction of CYP 3A, CYP 2C, and UGTs caused by phenobarbital. 
• Growth factors such as age, body weight can be important covariates to BUP exposure levels in newborns, given 
the fact of the significant changes of body fat content and enzyme levels of CYP 3A, 2C8, 2C9, 2C18 and 2C19.
• Dose adjustment is needed for BUP therapy in newborns based on lower sublingual bioavailability estimated in 
newborn patients, compared to 50% of BUP sublingual bioavailability observed in adults, and drug-drug interaction 
induced by phenobarbital. A larger, double-blind, properly powered clinical trial on BUP in young infants will 
enhance and validate this model and simulation. 
CONCLUSIONS
• Nonlinear mixed-effect modeling was employed to characterize the 
pharmacokinetics of BUP and NBUP based on data from a pilot clinical trial in 
12 newborn patients with NAS (Pediatrics, 2008, 122, e601-607). 
• Population PK analysis was performed using non-linear mixed-effects modeling  
with the NONMEM software, Version VI, Level 1.1. 
• One compartment model with first order absorption, metabolism, and 
elimination was developed in describing the PK of BUP and NBUP.
MODEL DEVELOPMENT
1. To characterize PK and sublingual bioavailability of buprenorphine (BUP) in 
target population during newborn period.
2. To evaluate the developmental changes in newborns in order to assist dosing 
optimization in ongoing clinical studies. 
OBJECTIVES
Background: About 55 to 94% of infants born to opioid dependent mothers 
have neonatal abstinence syndrome (NAS). Buprenorphine (BUP) is used 
clinically as an analgesic and a detoxification agent and a maintenance 
treatment for opioid dependence. No data, however, has been reported about 
the use of sublingual administration of BUP below the age of 4 year, especially 
for term infants with NAS. 
Objectives: Characterize pharmacokinetics (PK) of BUP in newborn patients; 
Evaluate the developmental changes in newborns in order to assist dosing 
optimization in ongoing clinical studies. 
Methods: In silico prediction of PK behavior and physiological development in 
newborn patients were evaluated using SIMCYP. Intravenous clearance was 
predicted through physiologically based simulation method in SIMCYP. Based 
on sublingual clearance obtained from a one compartmental model developed 
previously using NONMEM, individual changes of sublingual bioavailability 
were evaluated with physiological development in the first one and half month 
during the newborn period. 
Results: Intrinsic clearance of BUP in newborns were incorporated into enzyme 
kinetic data obtained from literature. Change of sublingual bioavailability for 
newborns was evaluated with bioavailability-postmenstrual age profiles. 
Sublingual bioavailability of BUP was estimated as 8.9--56.6% in newborn 
patients studied during the first one and half postnatal month. 
Conclusion: Developmental considerations for the PK of BUP in newborns are 
important for the characterization of the dose-exposure relationship. We have 
evaluated this from “bottom-up” and “top-down” approaches with SIMCYP and 
NONMEM respectively and found these approaches to be complementary and 
valuable for clinical trial design and routine clinical care. Presumably they 
would facilitate rational decision making in pediatric drug development as well.
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Jefferson University, Philadelphia, PA 19107; 3Department of Pediatric and Neurology, Thomas Jefferson University, Philadelphia, PA 19107; 4Department of Pediatrics, University of 
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• BUP is a semi-synthetic opioid derived from thebaine and used in clinics as an 
analgesic and as a detoxification and maintenance treatment for opioid
dependence.
• BUP is administered via intravenous and sublingual routes, since BUP has very 
low oral bioavailability due to extensive first-pass metabolism. 
• BUP has large volume of distribution and is extensively metabolized to 
norbuprenorphine (NBUP) by N-dealkylation mediated mainly by CYP3A4 (65%) 
and CYP2C8 (30%).
• BUP is metabolized in other metabolic pathways to a minor extent by CYP 2C9, 
2C18, and 2C19 and to a major extent by CYP 3A. 
• Both BUP and NBUP undergo glucuronidation by UGT1A3, 1A8, and 2B7.
• NAS occurs in 55 to 94% of infants who are born to opioid-dependent mothers. 
• No data  has been reported about the use of sublingual administration below 
the age of 4 year, especially for term infants with NAS. Therefore, there is a 
great need to determine the PK characteristics to optimize pediatric therapy.
INTRODUCTION
MODEL DESCRIPTION
• The population pharmacokinetic model is based on data from 12 newborn patients with NAS. Three newborn patients 
(ID13, 22, & 27) were co-treated with phenobarbital during certain period of treatment. 
• Simulation of intravenous clearance of BUP was conducted in 12 newborn patients with NAS. 
• In vitro enzyme kinetic data was incorporated into SIMCYP to simulate intravenous clearance in newborn patients.
* molecular weight, pKa, log P *dose
* unbound fraction in plasma (fu) *dose interval
* average renal clearance in adult *blood to plasma ratio
* Vmax and Km values derived using human liver microsomes /recombinant CYPs
* unbound fraction in human liver microsomes /recombinant CYPs (fuMic)
• Sublingual bioavailability was estimated by comparing intravenous clearance (CLiv) obtained from SIMCYP 
simulation to sublingual clearance (CLsub) generated using non-linear mixed effect modeling with NONMEM.
• Sublingual bioavailability—PMA profiles were drawn from the time they were born till BUP treatment completed for 
each of the 12 newborn patients.
SIMULATION with SIMCYP
Table 1   Summary of demographic characteristics for neonates (N = 12)  
at baseline 
Covariate Statistic Summary 
Gestational Age (weeks) Mean (SD) 
Median (min, max) 
39.28 (1.06) 
39.31 (37, 41) 
Postnatal Age (days) 
 
Mean (SD) 
Median (min, max) 
22 (11) 
17 (11, 47) 
Postmenstrual Age 
(PMA) (weeks) 
Mean (SD) 
Median (min, max) 
41.9 (1.22) 
42.15 (39.6, 43.55) 
Weight (kg) Mean (SD) 
Median (min, max) 
3.002 (0.347) 
3.060 (2.39, 3.459) 
Gender 
    Male 
    Female 
 
Number (%) 
Number (%) 
 
10 (83.3%) 
2 (16.7%) 
Race 
    White 
    Hispanic / Latino 
 
Number (%) 
Number (%) 
 
10 (83.3%) 
2 (16.7%) 
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operation and installation of SIMCYP software.
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Table 2     Treatment information 
Subject Treatment 
starting date  
from birth 
(days) 
 Treatment 
duration 
(days) 
Co-medication  
with phenobarbital 
AN06 1 14 No 
AN09 4 15 No 
AN12 4 17 No 
AN13 3 30 Yes 
(started at 143.29 hr  
& stopped at 287.29 hr) 
AN15 1 15 No 
AN16 3 16 No 
AN18 4 11 No 
AN19 2 24 No 
AN22 2 47 Yes 
(started at 222.62 hr  
& stopped at 381.5 hr) 
AN25 1 26 No 
AN27 2 39 Yes 
(started at 121.09 hr 
& stopped at 409.09 hr ) 
AN28 2 15 No 
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